IMMUNOME INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On January 10, 2022, Immunome, Inc. issued a press release providing an update regarding its investigational new drug (IND) submission to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). A copy of the press release is attached as Exhibit 99.1 to this report and incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
  No.                                      Description

  99.1       Press Release dated January 10, 2022.
104        Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses